Matrixyl and Matrixyl 3000: What the Evidence Shows

Start with our pillar guide: Best Peptides for Skin: Peptide Ingredients in Skincare Ranked by Evidence, or browse all Peptide Science articles.

Matrixyl is Sederma's trade name for palmitoyl pentapeptide-4, a signal peptide that may reduce fine lines. A 12-week, Procter & Gamble-funded split-face trial in 93 women found it worked better than placebo at 3 ppm, and a small 2023 trial supported that result. Matrixyl 3000 is a different blend of two peptides, and nearly all its data come from manufacturers or multi-ingredient products. Evidence: limited (Matrixyl); early/preliminary (Matrixyl 3000).

Matrixyl and Matrixyl 3000 are two of the most common peptide names on serum labels, but they don't contain the same molecules. They also aren't backed by the same evidence. In this guide we sort out which peptide is which, what the human studies actually measured, and where the data run out. For background on the wider category, start with our guide to peptide skincare ingredients.

Key takeaways

• Matrixyl (palmitoyl pentapeptide-4) has two controlled human trials: one with 93 women (Robinson et al., 2005) and one with 21 women (Aruan et al., 2023).
• Matrixyl 3000 (palmitoyl tripeptide-1 + palmitoyl tetrapeptide-7) has no independent randomized trial that we could find in PubMed.
• The only in-vivo penetration study covers Matrixyl 3000. It used 3 volunteers and found the peptides in the stratum corneum, the skin's outermost layer (Trzaska et al., 2026).
• No trial has tested Matrixyl and Argireline together. One small trial compared them directly, and Matrixyl came out ahead.
• Retinoids still have stronger evidence. The widely quoted brochure figures from Sederma haven't been published in a peer-reviewed paper.

What is Matrixyl?

Matrixyl is a trade name owned by Sederma, an ingredient supplier. Over time the brand has covered several different peptide complexes. The original Matrixyl is palmitoyl pentapeptide-4, a five-amino-acid peptide (KTTKS) with a palmitic acid chain attached. The fatty-acid tail makes the peptide more oil-friendly, which may help it get into skin. Researchers often shorten it to pal-KTTKS.

The EU's official cosmetic ingredient database, CosIng, lists palmitoyl pentapeptide-4 as the "reaction product of palmitic acid and Pentapeptide-4" with the function "skin conditioning – miscellaneous." CosIng does not list an anti-wrinkle function, because that database records cosmetic functions rather than efficacy claims.

You will also see an older INCI name (INCI is the standardized ingredient naming system used on labels). A 2019 review refers to pal-KTTKS as "Matrixyl® or palmitoyl pentapeptide-3" (Tałałaj et al., 2019). Palmitoyl pentapeptide-3 and palmitoyl pentapeptide-4 are the same molecule under two names.

What is the difference between Matrixyl, Matrixyl 3000 and Matrixyl synthe'6?

The newer Matrixyl products swap in different peptides. Treat each one as a separate ingredient with its own evidence.

The practical point: a product labeled "Matrixyl 3000" does not contain the peptide tested in the 93-person trial. To see how this family compares with copper peptides, read Matrixyl vs copper peptides.

How does Matrixyl work?

Matrixyl is classed as a signal peptide. That means a short peptide meant to tell skin cells, especially fibroblasts (the cells that make collagen), to produce more matrix proteins. A 2009 review sorted cosmetic peptides into 4 groups: signal, enzyme-inhibitor, neurotransmitter-inhibitor and carrier peptides (Gorouhi & Maibach, 2009).

You'll also see Matrixyl called a matrikine. A matrikine is a small fragment of a structural skin protein that can act as a messenger, prompting cells to repair or rebuild matrix. That is the idea behind Matrixyl, though it isn't proof that it works in living skin.

The lab data are real but limited. In cultured human dermal and corneal fibroblasts, pal-KTTKS increased collagen production in a concentration-dependent way. The effect peaked near the concentration where the peptide starts to self-assemble into aggregates (Jones et al., 2013). Evidence: lab only. More collagen from cells in a dish does not mean more collagen in your face.

Stability looks reasonable. In a skin-homogenate assay, pal-KTTKS resisted protease breakdown for up to 8 hours (Errante et al., 2021). One author worked part-time for a peptide manufacturer.

What does the human evidence show for Matrixyl?

2 double-blind, placebo-controlled trials found palmitoyl pentapeptide-4 improved wrinkles more than placebo. The larger one was run by a skincare company.

Robinson 2005 (n=93, 12 weeks). Procter & Gamble scientists randomized 93 Caucasian women aged 35 to 55 to a split-face design: a moisturizer with 3 ppm pal-KTTKS on one side and the same moisturizer without it on the other. After 12 weeks, both quantitative image analysis and expert graders found significantly greater improvement in wrinkles and fine lines on the peptide side. Participants also rated their own skin as improved, and the cream was well tolerated (Robinson et al., 2005). Evidence: limited.

That trial is well designed for a cosmetic study, since the split-face setup controls for each person's own skin. But P&G sold peptide products, and the trial has not been independently repeated at the same size.

Aruan 2023 (n=21, 8 weeks). This double-blind RCT split 21 Indonesian women aged 26 to 55 into 3 arms: an acetyl hexapeptide-3 (Argireline) cream, a palmitoyl pentapeptide-4 cream, or placebo. Each was applied twice daily around the eyes for 8 weeks. The team measured hydration, water loss, elasticity and crow's feet grading. The palmitoyl pentapeptide-4 group did better than both the Argireline and placebo groups (Aruan et al., 2023). No conflicts of interest were declared. Concentrations were not reported in the abstract. Evidence: early/preliminary.

The authors call it an "initial study" that needs more participants and a longer follow-up. With about 7 people per arm, that caveat is fair.

Is there human evidence for Matrixyl 3000?

We found no independent randomized trial of Matrixyl 3000 in PubMed. The available human data come from the manufacturer or from products that mix in several other actives.

• Mondon 2015 (Sederma authors). This methods paper tested a blend of palmitoyl oligopeptide and palmitoyl tetrapeptide-7, the two Matrixyl 3000 components. It reported improvements in dermal echography (ultrasound) and in reflectance confocal microscopy measures of the extracellular matrix vs placebo (Mondon et al., 2015). Sample size was not reported in the abstract, and the authors described the results as preliminary. Evidence: early/preliminary.
• Yang 2024 (formulator authors). A 12-week uncontrolled before-and-after study of an eye cream containing palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, a yeast/rice ferment and N-acetylneuraminic acid. It reported hydration +28.12%, elasticity +18.81% and ultrasound collagen density +54.99% (Yang et al., 2024). Most authors worked for the company that made the cream, although no conflict was declared. There was no placebo arm, and sample size was not reported in the abstract. Evidence: early/preliminary.

With 4 actives in one cream and no control group, nobody can say how much of the Yang result came from the peptides. A 2025 review of GHK-based peptides also noted a "surprising absence of clinical studies" for palmitoyl-GHK, which is the tripeptide half of Matrixyl 3000 (Mortazavi et al., 2025).

Does Matrixyl 3000 penetrate skin?

Matrixyl 3000 peptides reached every layer of the stratum corneum in a 3-person study. Nobody has shown that they reach the dermis, where fibroblasts live.

In a 2026 study by University of Nottingham researchers and No7/Boots employees, 3 healthy women applied a Matrixyl 3000 serum. Samples were taken at 0.5, 2 and 5 hours. Both palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 were found throughout the stratum corneum, with levels falling at deeper layers and no significant change over time. The peptides sat on the outer surfaces of skin cells (the intercellular route), not inside them (Trzaska et al., 2026). Evidence: early/preliminary.

This study is about Matrixyl 3000 only. We found no comparable in-vivo human penetration data for palmitoyl pentapeptide-4.

The general problem is well documented. A 2022 review concluded that most anti-wrinkle peptides are poor candidates for skin permeation, because of high molecular weight, water-loving structure and vulnerability to skin enzymes. The same review noted that permeability can be improved for some peptides, including KTTKS and GQPR, using chemical modification, enhancers, microneedles or nanocarriers (Mortazavi & Moghimi, 2022). Our explainer on whether peptides absorb into skin covers this in more depth.

What concentration of Matrixyl is used?

The positive 93-person trial used just 3 ppm (0.0003%) palmitoyl pentapeptide-4. US formulations top out at 0.0012% in leave-on products.

The Cosmetic Ingredient Review (CIR), the US industry-funded safety panel, published a 2024 report on pentapeptides. It recorded palmitoyl pentapeptide-4 in 239 formulations, 223 of them leave-on. The highest reported leave-on concentration was 0.0012%, in eye lotions (CIR Final Report, 2024).

Those numbers look tiny, and they are. Peptides like this are expected to work at very low concentrations. Labels rarely state the pure peptide percentage, though. They usually list the supplier's trade complex, which is mostly carrier solution. That distinction matters for the next 2 sections.

Can you use Matrixyl and Argireline together?

Yes, people commonly use them together, but no trial has tested Matrixyl and Argireline as a combination. The only head-to-head trial found palmitoyl pentapeptide-4 did better than Argireline used alone.

That head-to-head study is Aruan 2023, described above: 21 women, 8 weeks, 3 arms (Aruan et al., 2023). It compared the peptides against each other. It did not test them layered together.

The case for pairing them rests on their different proposed mechanisms:

• Matrixyl is a signal peptide meant to boost matrix production (lab data only for that mechanism).
• Argireline (acetyl hexapeptide-8) is a neurotransmitter-inhibiting peptide. In vitro, it interferes with the SNARE complex that releases nerve signals to muscles, with potency similar to botulinum toxin A but "much lower efficacy" (Blanes-Mira et al., 2002). An FDA in-vitro study found no Argireline in the dermis of human skin after 24 hours (Kraeling et al., 2015).

Different mechanisms are a reasonable theory for combining them, not evidence that the pair works better. Evidence for the combination: none. For more on each, see Argireline vs Matrixyl and what Argireline does.

Practical layering (convention, not evidence). A recurring question in skincare communities is where to put Argireline and Matrixyl 3000 in a routine, and whether to apply them to damp skin or after toner. The usual approach is to apply water-based serums thinnest to thickest, before moisturizer. Many people use Argireline on expression lines such as the forehead and crow's feet, and a Matrixyl serum more broadly. None of this ordering has been tested in a study.

What does the 10% in The Ordinary Matrixyl 10% + HA mean?

The Ordinary's serum lists palmitoyl tripeptide-1, palmitoyl tetrapeptide-7 and palmitoyl tripeptide-38 on its official ingredient list. That makes it Matrixyl 3000 plus Matrixyl synthe'6. Retail copy describes the two at "a combined concentration of 10%."

2 points follow from that:

1. The 10% refers to the supplier complexes, not pure peptide. Trade complexes are peptides diluted in carrier solution, so the actual peptide content is far lower than 10%.
2. It contains no palmitoyl pentapeptide-4, the peptide tested in the 93-person Robinson trial.

We found no published trial of this specific product.

Is Matrixyl better than a retinoid?

Retinoids have a much deeper evidence base than Matrixyl. A large body of trials and reviews covers their effects on photoaging (Mukherjee et al., 2006).

For a single benchmark: in a 24-week RCT of 36 elderly participants (mean age 87), 0.4% retinol applied to the arms up to 3 times weekly changed fine wrinkle scores by −1.64, compared with −0.08 for vehicle. It also increased glycosaminoglycans and procollagen I in skin biopsies (Kafi et al., 2007). Evidence for retinoids overall: well-established.

You can't compare these numbers directly with Robinson's. The 2 trials used different scales, body sites and populations. The CIR report mentions an 8-week study in 196 women comparing a multi-ingredient regimen (including palmitoyl pentapeptide-4, niacinamide and retinyl propionate) with prescription 0.02% tretinoin. But the peptide concentration wasn't provided, and the mix makes it impossible to isolate the peptide's effect (CIR, 2024).

Many people use both. Our guide to using peptides with retinol covers how. For prescription retinoids, talk to a dermatologist.

What about the Sederma brochure numbers?

You'll often see claims that Matrixyl cut "wrinkle density by 68%" and "depth by 45%." These figures come from supplier marketing materials. We could not find a peer-reviewed source for them, so treat them as unverified. They are not results from the Robinson or Aruan trials.

Is Matrixyl safe?

In the 93-person Robinson trial, the 3 ppm cream was well tolerated over 12 weeks (Robinson et al., 2005). Its main US use is in leave-on products at or below 0.0012% (CIR, 2024).

One RCT of 20 breast cancer patients having radiotherapy compared a cream containing Matrixyl and other actives with Bepanthol lotion. Skin toxicity didn't differ, but mild itching and sporadic skin eruptions were more frequent with the Matrixyl-containing cream, and one suspected allergic reaction occurred (Röper et al., 2004). Because that was a multi-ingredient cream on irradiated skin, it can't tell us how Matrixyl alone behaves on everyday skin. Patch test new products, and ask your oncology team before applying anything to treated skin.

Where the evidence stops

• No independent replication at scale. The largest Matrixyl trial (n=93) was run by P&G, and the only other controlled trial had 21 participants.
• Matrixyl 3000 lacks independent RCTs. Its data come from Sederma or from formulators testing multi-ingredient products.
• Synthe'6 has no peer-reviewed human data that we found.
• No combination trials. Matrixyl with Argireline, retinoids or vitamin C hasn't been tested as a pair against each ingredient alone.
• Penetration is partly mapped. Matrixyl 3000 reaches the stratum corneum in 3 people. Whether either Matrixyl reaches fibroblasts in living human skin is unknown.
• Long-term use. No trial ran longer than 12 weeks.

FAQ

Is Matrixyl the same as Matrixyl 3000? No. Matrixyl is palmitoyl pentapeptide-4, and Matrixyl 3000 combines palmitoyl tripeptide-1 with palmitoyl tetrapeptide-7. The 93-person trial tested the original Matrixyl only (Robinson et al., 2005).

What concentration of Matrixyl is effective? The positive Robinson trial used 3 ppm (0.0003%) palmitoyl pentapeptide-4 in a moisturizer. The highest reported US leave-on concentration is 0.0012% (CIR, 2024). No study has established the best dose.

Can you use Matrixyl and Argireline together? Many people do, and the 2 peptides have different proposed mechanisms. But no trial has tested them together. The only head-to-head trial (n=21) found palmitoyl pentapeptide-4 did better than Argireline alone (Aruan et al., 2023).

Is Matrixyl better than retinol? The evidence doesn't support that. Retinoids are backed by many trials and reviews, including a 24-week RCT of 0.4% retinol (Kafi et al., 2007). Matrixyl has 2 small-to-moderate controlled trials, and no trial has compared the 2 directly.

Does Matrixyl absorb into the skin? For Matrixyl 3000, a 3-person study detected both peptides throughout the stratum corneum within 30 minutes (Trzaska et al., 2026). Deeper penetration hasn't been shown. We found no in-vivo human penetration data for palmitoyl pentapeptide-4.

Does The Ordinary Matrixyl 10% + HA contain 10% peptide? No. The 10% refers to the combined Matrixyl 3000 and Matrixyl synthe'6 trade complexes, which are mostly carrier solution. The product also contains no palmitoyl pentapeptide-4.

References

1. Robinson LR, et al. Int J Cosmet Sci. 2005. Double-blind, placebo-controlled, randomized split-face trial; n=93 women aged 35–55; 12 weeks; 3 ppm pal-KTTKS; Procter & Gamble authors. https://pubmed.ncbi.nlm.nih.gov/18492182/
2. Aruan RR, et al. J Clin Aesthet Dermatol. 2023. Double-blind RCT, 3 arms (acetyl hexapeptide-3, palmitoyl pentapeptide-4, placebo); n=21 women aged 26–55; 8 weeks; no conflicts declared. https://pubmed.ncbi.nlm.nih.gov/36909866/
3. Jones RR, et al. Mol Pharm. 2013. In vitro, human dermal and corneal fibroblasts; C16-KTTKS and collagen production. https://pubmed.ncbi.nlm.nih.gov/23320752/
4. Mondon P, et al. J Cosmet Dermatol. 2015. Methods study, placebo comparison; Matrixyl 3000 components; Sederma authors; sample size not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/25817264/
5. Yang F, et al. Skin Res Technol. 2024. Uncontrolled before/after study, multi-ingredient eye cream; 12 weeks; formulator authors; sample size not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/38932444/
6. Trzaska AH, et al. Int J Pharm. 2026. In vivo penetration study; n=3 healthy women; Matrixyl 3000 serum; University of Nottingham and No7/Boots authors. https://pubmed.ncbi.nlm.nih.gov/42790608/
7. Tałałaj U, et al. Molecules. 2019. Review; naming of pal-KTTKS as Matrixyl/palmitoyl pentapeptide-3. https://pubmed.ncbi.nlm.nih.gov/31618846/
8. Gorouhi F, Maibach HI. Int J Cosmet Sci. 2009. Review; 4 classes of cosmetic peptides. https://pubmed.ncbi.nlm.nih.gov/19570099/
9. Mortazavi SM, Moghimi HR. Skin permeability, a dismissed necessity for anti-wrinkle peptide performance. Int J Cosmet Sci. 2022. Review. https://pubmed.ncbi.nlm.nih.gov/35302659/
10. Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Bioimpacts. 2025. Review of GHK and palmitoyl-GHK; no conflicts declared. https://pubmed.ncbi.nlm.nih.gov/39963574/
11. Errante F, et al. J Pharm Biomed Anal. 2021. Skin-homogenate stability assay; one author part-time at Espikem. https://pubmed.ncbi.nlm.nih.gov/33281001/
12. Blanes-Mira C, et al. Int J Cosmet Sci. 2002. Rational-design and in vitro study of acetyl hexapeptide-8; developer research. https://pubmed.ncbi.nlm.nih.gov/18498523/
13. Kraeling ME, et al. Cutan Ocul Toxicol. 2015. In vitro diffusion-cell study, human cadaver and hairless guinea pig skin; US FDA authors. https://pubmed.ncbi.nlm.nih.gov/24754410/
14. Kafi R, et al. Arch Dermatol. 2007. RCT, 0.4% retinol vs vehicle; n=36 elderly participants; 24 weeks. https://pubmed.ncbi.nlm.nih.gov/17515510/
15. Mukherjee S, et al. Clin Interv Aging. 2006. Review of retinoid efficacy and safety. https://pubmed.ncbi.nlm.nih.gov/18046911/
16. Röper B, et al. Strahlenther Onkol. 2004. RCT; n=20 breast cancer patients during radiotherapy; multi-ingredient cream with Matrixyl vs Bepanthol lotion. https://pubmed.ncbi.nlm.nih.gov/15127162/
17. Cosmetic Ingredient Review. Final Report: Pentapeptides. September 2024. Safety assessment and use-concentration data. https://www.cir-safety.org/sites/default/files/FR_Pentapeptides_092024.pdf
18. European Commission. CosIng cosmetic ingredient database: Palmitoyl Pentapeptide-4, Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7. Checked October 2026. https://ec.europa.eu/growth/tools-databases/cosing/

Disclosure: This article contains no affiliate links, and no brand paid for or reviewed it. It summarizes published research for general education and is not medical advice. For prescription treatments, skin conditions or skin undergoing medical treatment, consult a dermatologist or your care team.

For educational purposes only; not medical advice. See our disclaimer and research method.